Meta-analysis of the efficacy and safety of repaglinide in Chinese type 2 diabetes

Objective To evaluate the comparative efficacy and safety of repaglinide against other hypoglycemic agents in Chinese T2DM patients. Methods The MEDLINE?,EMBASE?and CENTRAL were searched and qualified studies were included. Results Totally 96qualified studies were included.In terms of HbA1c decline,repaglinide treatment was superior to placebo(WMD:-0.87%,95%CI:-1.21~-0.53)or sulfonylureas(SUs)(WMD:-0.23%,95%CI:-0.41~-0.06),and was comparable with nateglinide,metformin,α-glucosidase inhibitors(AGIs)or TZDs.In terms of fasting glucose lowering,repaglinide treatment was superior to placebo(WMD:-1.50mmol/L,95%CI:-1.95~-1.05),nateglinide(WMD:-0.17mmol/L,95%CI:-0.30~-0.05)or SUs(WMD:-0.24mmol/L,95%CI:-0.46~-0.01),and was comparable with metformin,AGIs or TZDs.In terms of postprandial glucose lowering,repaglinide treatment was superior to placebo,AGIs,metformin or SUs,and was comparable with nateglinide or TZDs.In terms of BMI,repaglinide treatment was superior to SUs.In terms of hypoglycemic rate,repaglinide treatment was superior to SUs,and was comparable with nateglinide. Conclusion This Meta-analysis provides more comprehensive clinical evidence on the comparative efficacy and safety of repaglinide in treating Chinese T2DM patients.